Data mining of the FDA adverse event database identified Raynaud's phenomenon as a novel safety signal associated with all CGRP antagonists, with network pharmacology suggesting involvement of IGF1R pathways.
Novel Raynaud's signal detectedAll CGRP antagonists showed statistically significant association with Raynaud's phenomenon in FDA FAERS data
What the researchers found
Raynaud's phenomenon was identified as a novel safety signal for all CGRP antagonists using FAERS data mining (PRR ≥2, chi-square ≥4, ROR lower 95% CI >2), with IGF1R pathway involvement suggested by network pharmacology.
Why it matters
CGRP is a powerful vasodilator, so blocking it could theoretically constrict blood vessels. This signal confirms that concern. Patients with pre-existing Raynaud's or vascular conditions should be monitored when starting CGRP antagonists for migraine.
The numbers in context
Data covered reports from 2004 Q1 to 2022 Q3 in the US FAERS database.
How the study worked
Data mining of FDA FAERS database (2004 Q1 - 2022 Q3) using reporting odds ratio and proportional reporting ratio algorithms. Network pharmacology using Cytoscape 3.7.2 and molecular docking with Glide (Schrödinger) to explore mechanistic pathways.
Who was studied
Patients reporting adverse events while using CGRP antagonists
What this study cannot tell us
FAERS data mining identifies signals but cannot establish causation. Reporting bias is inherent in adverse event databases. The IGF1R pathway involvement is computational prediction, not experimentally validated. The actual incidence of Raynaud's with CGRP drugs cannot be determined from this analysis.
How to read the evidence
Preliminary evidence from pharmacovigilance data mining and computational analysis. Establishes a safety signal requiring clinical investigation.
When this study was published
Published in 2024. Relevant as CGRP antagonist prescriptions continue to grow rapidly.
The bigger picture
As CGRP antagonists become widely prescribed for migraine prevention, understanding their vascular side effects becomes increasingly important. CGRP's role in maintaining blood vessel dilation means blocking it could have consequences for peripheral circulation, particularly in susceptible individuals.
Questions still open
- Should patients with pre-existing Raynaud's avoid CGRP antagonists or be monitored more closely?
- Is the Raynaud's risk different between CGRP ligand blockers and CGRP receptor blockers?
- Does the IGF1R mechanism offer a target for preventing this vascular side effect?
Common questions
What is Raynaud's phenomenon and why might CGRP drugs cause it?
Should I stop my CGRP migraine medication if I have cold fingers?
Read the original research
Identification of novel signal of Raynaud's phenomenon with Calcitonin Gene-Related Peptide(CGRP) antagonists using data mining algorithms and network pharmacological approaches.
Expert opinion on drug safety, 23(2), 231-238
Citation
Singh, Rima; Kumar, Anoop; Lather, Viney; Sharma, Ruchika; Pandita, Deepti. (2024). Identification of novel signal of Raynaud's phenomenon with Calcitonin Gene-Related Peptide(CGRP) antagonists using data mining algorithms and network pharmacological approaches.. Expert opinion on drug safety, 23(2), 231-238. https://doi.org/10.1080/14740338.2023.2248877